Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Glucocorticoid receptor inhibitor polypeptide and application

A technology of receptor inhibitors and glucocorticoids, applied in the field of glucocorticoid receptor inhibitor polypeptides, can solve problems such as the treatment of depression with glucocorticoid receptor inhibitors that have not been reported in research

Inactive Publication Date: 2017-01-25
SUZHOU PULUODA BIOLOGICAL SCI & TECH
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, no studies have reported the use of glucocorticoid receptor inhibitors in the treatment of depression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glucocorticoid receptor inhibitor polypeptide and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Effects of glucocorticoid receptor inhibitor peptides on plasma glucocorticoid levels in chronic unpredictable stress model rats.

[0017] SD rats were used as test animals, and 60 rats, half male and half male, with a body weight of 180-220 g, were randomly divided into 6 groups, high-dose group, middle-dose group, low-dose group, positive control group, model group, Blank group, each group l0. Establish a rat chronic unpredictable stress model: the stress content is: restraint for 4 hours; wet bedding overnight; shaking for 1 hour (160r / min); fasting for 12 hours; Clamp the tail for 1 min; crowd overnight (8 / cage). Two stresses were used during the day, and one stress was used at night, and the stress was continued for 4 weeks. Administer after the last stimulation. Dosing regimen: the treatment group was subcutaneously injected with the polypeptide of the present invention at doses of 20, 10, and 5 mg / Kg, the control group was given fluoxetine at a dose of 10 mg / K...

Embodiment 2

[0023] Effects of glucocorticoid receptor inhibitor peptides in a mouse forced-swim stress-despair model.

[0024] Using ICR mice as the test animals, 50 mice, half male and half male, weighing 18-22g, were randomly divided into 5 groups: high-dose group, middle-dose group, low-dose group, positive control group, blank group, Each group l0. The treatment group was subcutaneously injected with the polypeptide of the present invention at doses of 20, 10, and 5 mg / Kg, the control group was given fluoxetine at a dose of 10 mg / Kg, and the blank group was given normal saline for 7 consecutive days. One hour after administration on the seventh day, the mice were subjected to a forced swimming test. The mice were forced to swim in water at 20-25°C for 6 minutes, and the immobility time within 4 minutes after recording was recorded. The time spent floating with the head out of the water is used to evaluate the effect of the polypeptide of the present invention on the model of mouse fo...

Embodiment 3

[0030] Effects of glucocorticoid receptor inhibitor peptides on a mouse tail-suspension stress hopelessness model.

[0031] Using ICR mice as the test animals, 50 mice, half male and half male, weighing 18-22g, were randomly divided into 5 groups: high-dose group, middle-dose group, low-dose group, positive control group, blank group, Each group l0. The treatment group was subcutaneously injected with the polypeptide of the present invention at doses of 20, 10, and 5 mg / Kg, the control group was given fluoxetine at a dose of 10 mg / Kg, and the blank group was given normal saline for 7 consecutive days. 1h after administration on the 7th day, the mice were subjected to a tail-suspension test, and the mice were fixed with adhesive tape at a place about 1 cm from the end of their tails, and the mice were kept in a suspended state for 6 minutes, and the immobility time of 4 minutes after recording was used to evaluate this product. Effects of Invention Peptides on a Mouse Tail Sus...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines, in particular to polypeptide for inhibiting a glucocorticoid receptor and relieving depressive symptoms. The sequence of the polypeptide is SED ID NO:1, which is a brand new sequence. The polypeptide provided by the invention has the beneficial effects that the polypeptide can reduce the glucocorticoid content of chronic unpredictable stress model rat plasma. In-vivo pharmacological results indicate that the polypeptide provided by the invention can improve the depressive symptoms of acute and chronic depression model animals and can serve as an effective candidate treatment method for clinical depression.

Description

technical field [0001] The invention relates to a glucocorticoid receptor inhibitor polypeptide and application thereof, in particular to a polypeptide capable of inhibiting glucocorticoid receptors and alleviating depression symptoms. Background technique [0002] Depression is an affective disorder. Clinically, it is characterized by lack of interest, low mood, and sleep disturbance as the main symptoms. Some patients are often accompanied by suicidal tendencies. In recent years, the World Health Organization called it an "invisible burden". The report pointed out that about 350 million people are currently suffering from depression, and nearly one million people commit suicide due to depression every year. Depression not only brings great mental torture to the patient himself, but also brings a heavy burden to the family and society. Therefore, it is particularly important to find new targets for the treatment of depression and develop new and effective drugs for the tre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/00A61K38/16A61P25/24
CPCA61K38/00C07K14/001
Inventor 罗瑞雪
Owner SUZHOU PULUODA BIOLOGICAL SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com